The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical evaluation of PARP inhibitors in combination with DNA-damaging agents in a Ewing sarcoma orthotopic xenograft model.
Elizabeth Stewart
No relevant relationships to disclose
David Ross Goshorn
No relevant relationships to disclose
Michael A. Dyer
No relevant relationships to disclose
Anang Shelat
No relevant relationships to disclose
Cori Bradley
No relevant relationships to disclose
Alberto S. Pappo
No relevant relationships to disclose
Amos Loh
No relevant relationships to disclose